Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by hyperglycemia resulting from a progressive loss of insulin secretion on the background of insulin resistance \[[@CR1], [@CR2]\]. The International Diabetes Federation has estimated that in 2015 the prevalence of diabetes was 8.8% and that this will have increased to 10.4% by 2040 \[[@CR3]\]. Approximately 87--91% of all people with diabetes in high income countries are estimated to have T2DM \[[@CR3]\]. Increases in obesity, physical inactivity, urbanization, and an aging and expanding population have contributed to the increasing prevalence of this disease \[[@CR3]--[@CR5]\]. If inadequately managed, diabetes can lead to heart attack, stroke, kidney disease, blindness, and amputation \[[@CR2], [@CR6], [@CR7]\].

The majority of T2DM patients require medication for glycemic control, often initiating with oral anti-diabetes drug (OAD) monotherapy and progressing to combination therapy or injectable treatment \[[@CR7]--[@CR9]\]. Medication adherence plays an essential role in overall glycemic control, and helps to reduce the risk of complications, to prevent premature mortality, and to lower overall healthcare costs \[[@CR10]--[@CR12]\]. Nevertheless, adherence rates as low as 45% have been reported among those with T2DM \[[@CR13]\]. Non-adherence has been associated with various treatment-related factors, including complex or frequent dosing, and treatment side effects \[[@CR10], [@CR13]\]. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have emphasized the importance of considering patients' preference for such treatment-related factors when clinical decisions around the management of T2DM are being made \[[@CR7]\]. Decisions that are patient centered are likely to improve adherence and consequently clinical outcomes \[[@CR10], [@CR14]\].

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a newer class of injectable T2DM treatments developed to target the incretin system \[[@CR15], [@CR16]\]. Agents in this class vary particularly with respect to key attributes (including dosing regimen and the risk of side effects) which have been associated with patient non-adherence \[[@CR17]--[@CR19]\].

The objective of this study was to examine the relative importance of treatment-related attributes in influencing preferences for GLP-1RAs among injection-naïve patients with T2DM in a wide geographic distribution \[the UK, Germany, China, Brazil, and Japan\]. Two commonly prescribed GLP-1RAs that were available at the time of the study and that differ in terms of key attributes influencing adherence (regimen and risk of side effects) were selected to explore preferences for treatments that differed with respect to these key features: once-weekly (QW) exenatide, the first approved once-weekly GLP-1RA treatment, and once-daily (QD) liraglutide, the most commonly prescribed once-daily GLP-1RA treatment.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a cross-sectional, descriptive study involving a one-time, Web-based discrete choice experiment (DCE) survey completed by injection-naïve T2DM patients.

DCE, a type of conjoint analysis, is a robust methodology to elicit consumer preferences and is increasingly being used to examine patient preferences for healthcare interventions \[[@CR20], [@CR21]\]. DCE assumes that any product or service can be described by its characteristics (or attributes) and that an individual values the product or service on the basis of the levels of these attributes. In a DCE, individuals are presented with hypothetical descriptions of products and are asked to choose their preferred product on the basis of the levels of attributes presented. Response data are modelled within a benefit (or satisfaction) function, which provides information on whether or not the given attributes are important, the relative importance of attributes, the rate at which individuals are willing to trade between attributes, and overall benefit scores for alternative products \[[@CR20]\].

In this study, the DCE survey was completed by adult T2DM patients in the UK, Germany, China, Brazil, and Japan. Eligibility was determined by the following criteria: patient-reported diagnosis of T2DM; age 18 years or older; adequate written and oral fluency in the target language; willing and able to complete a 30-min online survey to answer questions about treatment experiences and preferences; have access to the Internet; willing to provide informed consent; currently on an OAD; and no experience with injection treatment for T2DM (i.e., injection-naïve). Eligible participants were identified by a market research recruitment agency using multiple methods including searching databases of patients who had agreed to be contacted for participation in such research studies, referrals from clinicians and patient associations, and advertising in targeted publications. This study aimed to recruit a diverse sample with respect to age, gender, and education status.

The survey was programmed and hosted by Global Perspectives (Berkshire, UK) on a secure server. Interested participants were provided with an Internet link to the online Web-based DCE survey. All participants were screened online to ensure that they met the specific eligibility criteria. All eligible patients provided online consent through the Web link prior to completing the survey. Those who completed the survey received compensation for their participation.

The study protocol was approved by the Salus International Review Board (Austin, TX, USA). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013.

Survey Development {#Sec4}
------------------

A literature review and qualitative research with clinicians and T2DM patients were conducted to inform attribute selection and survey development. Open-ended, one-on-one interviews were conducted with 50 T2DM patients (from the five target countries) with experience taking GLP-1RAs or who were injection-naïve to identify and examine treatment attributes important to T2DM patients \[[@CR22]\].

On the basis of the findings from the literature and qualitative research, eight attributes related to treatment efficacy, safety, tolerability, and convenience were included in the DCE survey: efficacy \[improvement in glycated hemoglobin (HbA1c)\], common GLP-1RA side effects (nausea, diarrhea, vomiting, and injection site nodules), injection device size, needle size, need for titration, required injection preparation (associated with vial/syringe, single-use pen, multi-use pen, or auto-injector), evidence of long-term efficacy/safety, and dosing frequency (daily or weekly). The US Food and Drug Administration-approved labels of two common GLP-1 RAs \[[@CR23], [@CR24]\] were reviewed to provide profiles reflecting two hypothetical treatments (Fig. [1](#Fig1){ref-type="fig"}). One treatment was a profile of a daily injectable, approximating liraglutide QD, the most commonly prescribed daily GLP-1RA treatment. The other treatment was an injectable approximating exenatide QW, the first QW GLP-1RA treatment. Exenatide QW is delivered once weekly, does not require titration, and uses a thicker, longer needle. Delivery of exenatide was specified as either using a single-use pen device or via an auto-injector. The single-use pen device contains exenatide microspheres and lipid-based diluent in separate chambers, requiring careful preparation of the medication, while the auto-injector has the exenatide microspheres and lipid-based diluent prefilled in one chamber. Exenatide QW can also be delivered in a single-dose tray (vial and syringe). Liraglutide QD is delivered once daily via a multiple-use pen, requires careful preparation of the medication, requires titration of the medication, and uses a thinner, shorter needle.Fig. 1Example of a discrete choice experiment question comparing treatment profiles reflecting liraglutide QD and exenatide QW (Treatment A vs. Treatment B)

The attributes and levels were combined into choice sets using a published orthogonal array \[[@CR25]\]. An orthogonal fractional factorial design was used to identify the minimum specification of the DCE experimental design in order to fairly represent combinations of the attributes and levels. These combinations were paired using a fold-over design. Each choice question presented two hypothetical treatments (Treatment A or B) and participants were asked to indicate their preferred choice. On the basis of the orthogonal fractional factorial design, a total of 32 pairs of choice sets were generated, with each respondent being presented with a set of 16 unique paired choice sets \[[@CR20]\]. An example of a choice set included in the survey is provided in Fig. [1](#Fig1){ref-type="fig"}.

The first section of the survey consisted of questions on past and current medication use, adherence, clinical history, and demographic information. The adherence questions asked about frequency of missing, skipping, or being late in taking their oral medications and what aspect of their current medications made it most difficult or inconvenient to take as prescribed. In addition, participants were asked hypothetical questions about the potential impact of dosing frequency on their adherence.

The second section of the survey included the DCE questions. The DCE began by presenting participants with descriptions of the attributes and the levels included in the survey, followed by the 16 paired comparison questions. The English-language survey was pilot-tested with five T2DM patients in the UK, and revisions were made to improve clarity and assess cognitive and overall burden. The survey was then translated into Portuguese (Brazil), Chinese (China), German (Germany), and Japanese (Japan). Two native speakers in each country reviewed the translations for accuracy and clarity.

Data Analysis {#Sec5}
-------------

Descriptive statistics using SAS (v.4.3) were performed to calculate means, standard deviations, ranges, frequencies, and percentages as appropriate, for the demographic and clinical characteristics data, as well as self-reported data on adherence to medication. SAS (v.4.3) was also used to analyze the DCE data using a conditional or mixed logit model, with each attribute and level included as a separate variable in the model. The choice of treatment was the dependent variable and was analyzed conditionally for each choice set (i.e., each treatment choice the respondent had to make). The conditional logistic model provided regression coefficients (i.e., utility estimates), which were then presented as odds ratios (ORs) and their 95% confidence intervals (CI) in order to indicate the importance of a given attribute level versus a reference attribute level, as well as the likelihood of a respondent choosing a treatment with a given level of an attribute rather than a treatment with the reference level of the attribute. All analyses were performed for the total sample and separately for each country.

Sensitivity analyses were conducted to examine how much a product's overall preference was improved or worsened by changing certain attributes, while holding all other attributes at constant base case levels. For example, the exenatide QW profile was compared to the liraglutide QD profile assuming better efficacy for liraglutide QD versus exenatide QW. The exenatide QW profile assuming an auto-injector device size and auto-injector preparation was also compared to the liraglutide QD profile.

Results {#Sec6}
=======

Sample Characteristics {#Sec7}
----------------------

A total of 1482 injection-naïve respondents completed the survey (Table [1](#Tab1){ref-type="table"}). The mean age of patients in the study was 56 years (range 18--87 years) and 68% were male. The majority (52%) was White/Caucasian, employed (55%), and educated, with 52% having at least a college degree. The mean time since the diagnosis of T2DM was 7.0 years. The majority of participants had taken metformin to treat their diabetes (54% current users; 38% past users). The most commonly reported comorbidities were identified as "other" (19.7%), cardiovascular disease (11.8%), and mental health conditions (6.8%); however, more than half of respondents (53.5%) reported no other health conditions. A greater proportion of the respondents in the UK and Germany were retired. With the exception of country-related differences, the sociodemographic and clinical characteristics were similar across the countries (Table [1](#Tab1){ref-type="table"}).Table 1Sociodemographic and clinical characteristics of injection-naïve type 2 diabetes mellitus patientsPatient characteristicsTotal (*N* = 1482)Brazil (*n* = 296)China (*n* = 297)Germany (*n* = 296)Japan (*n* = 296)UK (*n* = 297)Mean age, years (SD)56.0 (11.4)51.7 (12.2)49.9 (9.2)58.8 (9.8)57.2 (11.4)62.3 (9.5)Male/female (%)68/3259/4154/4670/3088/1267/33Education (%) No formal qualifications4.61.40.09.50.311.8 GCSE/O-level or equivalent22.322.61.753.71.432.0 A-level or equivalent21.518.614.115.236.123.6 University degree43.739.281.518.256.123.2 Postgraduate degree8.018.22.73.46.19.4Ethnic group (%) White51.661.11.397.60.097.0 Mixed/multiple ethnic groups2.812.20.71.000.0 Asian40.71.799.70.3100.01.7 Black/African/Caribbean5.325.70.30.00.00.3 Arab0.20.30.30.30.00.0 Other0.20.70.00.00.00.3 Prefer not to answer0.50.30.01.00.01.0Employment (%) Employed, full-time39.839.280.822.340.516.2 Employed, part-time7.07.81.79.810.55.4 Self-employed8.316.94.05.111.14.4 Student0.51.40.00.30.70.0 Stay-at-home parent/homemaker2.51.00.03.44.43.7 Unemployed6.59.10.09.18.46.1 Retired31.721.613.543.622.057.9 Disabled2.80.30.06.41.75.4 Other0.92.70.00.00.71.0Comorbidities (%) Cancer2.22.00.32.72.04.0 Cardiovascular condition11.812.83.021.39.812.1 Chronic kidney disease1.61.40.03.70.72.4 Mental health condition6.81.74.714.28.15.4 Respiratory disorder5.15.10.79.13.77.1 Diabetic retinopathy3.02.04.40.32.45.7 Diabetic foot problems5.55.43.410.53.05.1 Diabetic neuropathy4.75.71.07.42.76.7 Other19.718.91.325.729.423.2 None53.554.183.235.149.345.8Time since diagnosis of T2DM, years \[range\]7.0 \[0.5, 61.9\]6.7 \[0.9, 39.3\]3.9 \[0.9, 49.8\]7.7 \[0.9, 61.9\]8.5 \[0.9, 52.8\]8.3 \[0.5, 47.1\]Mean HbA1c^a^, % (SD)7.4 (2.3)8.3 (4.0)9.1 (3.5)6.7 (1.1)7.0 (0.9)7.5 (2.7)*HbA1c* glycated hemoglobin, *SD* standard deviation, *T2DM* type 2 diabetes mellitus^a^ *n* = 682 (total), 73 (Brazil), 82 (China), 165 (Germany), 273 (Japan), and 89 (UK)

Current Treatments {#Sec8}
------------------

Overall, most patients were taking oral medication once (32.2%), twice (48.8%), or three times a day (16.7%). The majority of patients reported having no difficulty (82.7%) or little difficulty taking oral medication (10.7%). Overall, 46.8% of respondents indicated that they never missed a dose of their current medication. Among the remaining respondents, 8.6% missed a dose about once a year, 10.9% missed a dose about once every 6 months, 6.7% missed a dose once every 3 months, and 27.1% missed a dose at least once a month. Reasons for completely missing a dose included forgetting (65.7%), not having the medication with them at the scheduled time (27.8%), a change in daily routine (13.5%), and running out of medication (8.3%). More than half (52.7%) reported taking medication late, with the reasons including forgetting (55.6%), not having the medication with them at the scheduled time (28.6%), or experiencing a change in daily routine (21.1%).

Attributes Influencing Choice of Injectable Medication {#Sec9}
------------------------------------------------------

Total sample and country-specific analyses revealed that among the eight attributes included in the survey, side effects, efficacy, and dosing frequency were the top three attributes driving patient preference. Needle size, device size, and required injection preparation were the least important predictors of choice.

Across all countries, patients indicated a preference for a treatment associated with fewer side effects (OR 2.14; 95% CI 2.08, 2.20; *p* \< 0.001), a treatment offering a 1.5-point improvement in HbA1c (OR 1.85; 95% CI 1.77, 1.93; *p* \< 0.001), and a treatment that was administered once weekly (OR 1.63; 95% CI 1.59, 1.68; *p* \< 0.001). The relative importance of these attributes varied by country. Having fewer side effects was the most highly preferred attribute in the UK (OR 3.54; *p* \< 0.001), Japan (OR 2.55; *p* \< 0.001), Germany (OR 2.39; *p* \< 0.001), and Brazil (OR 2.00; *p* \< 0.001), but not in China where a treatment offering a 1.5-point improvement in HbA1c was the most highly preferred attribute (OR 2.67; *p* \< 0.001). Efficacy and dosing frequency were ranked second and third in all countries except China where side effects was second and Japan where dosing frequency was second and efficacy was third (Table [2](#Tab2){ref-type="table"}).Table 2Attributes influencing injection-naïve T2DM patients' preference for GLP-1RA injectionsAttributeLevel comparisonOdds ratio\* (95% CI)Total (*N* = 1482)Brazil (*n* = 296)China (*n* = 297)Germany (*n* = 296)Japan (*n* = 296)UK (*n* = 297)Side effectsExenatide QW vs. liraglutide QD profile2.14 (2.08, 2.20)2.00 (1.87, 2.13)1.27 (1.20,1.35)2.39 (2.23, 2.56)2.55 (2.37, 2.73)3.54 (3.28, 3.82)Efficacy1.5% vs. 0.8% improvement in HbA1c1.85 (1.77, 1.93)1.97 (1.78, 2.18)2.67 (2.42, 2.94)1.92 (1.73, 2.14)1.30 (1.17, 1.44)1.75 (1.57, 1.96)Dosing frequencyWeekly vs. daily1.63 (1.59, 1.68)1.75 (1.64, 1.87)1.19 (1.21, 1.27)1.71 (1.60, 1.83)2.24 (2.09, 2.41)1.69 (1.57, 1.82)Preparation requiredMost preferred preparation type^a^ vs. vial/syringe1.09 (1.03, 1.14)1.10 (0.98, 1.23) ns1.06 (0.96, 1.17) ns1.06 (0.94, 1.19) ns1.02 (0.91, 1.14) ns1.36 (1.20, 1.55)TitrationNo titration vs. titration1.12 (1.08, 1.15)1.09 (1.02, 1.16)0.99 (0.93, 1.05) ns1.15 (1.08, 1.23)1.17 (1.10, 1.26)1.23 (1.14, 1.32)Evidence of effectiveness and safety6 years vs. 1 year1.30 (1.25, 1.36)1.41 (1.28, 1.56)1.17 (1.07, 1.29)1.55 (1.40, 1.72)1.14 (1.03, 1.27)1.30 (1.16, 1.45)Device sizeMost preferred size^b^ vs. single-use pen1.04 (0.99, 1.09) ns1.06 (0.93, 1.20) ns1.02 (0.92, 1.13) ns0.99 (0.89, 1.11) ns1.14 (1.00, 1.31)1.07 (0.95, 1.20) nsNeedle sizeShorter/thinner vs. longer/thicker1.03 (1.00--1.06)1.05 (0.98--1.12) ns1.02 (0.96, 1.09) ns0.98 (0.92, 1.04) ns1.05 (0.98, 1.13) ns1.07 (1.00, 1.15) ns*CI* confidence interval, *HbA1c* glycated hemoglobin, *QD* once daily, *QW* once weekly\* All significant at *p* \< 0.05 unless noted as "ns" indicating not significant^a^Preferred preparation type was multi-use pen (total, Brazil, Germany, and the UK) or auto-injector (China and Japan)^b^Preferred device size was auto-injector (total, China, Germany, and the UK) or vial and syringe (Brazil, Japan)

Among the five device-related attributes, dosing frequency, titration, and the preparation required were significant predictors of choice in the total sample. Patients significantly preferred weekly to daily dosing in both the total sample (see above) and in each of the individual countries, including Japan (OR 2.24; *p* \< 0.001), Brazil (OR 1.75; *p* \< 0.001), Germany (OR 1.71; *p* \< 0.001), the UK (OR 1.69; *p* \< 0.001), and China (OR 1.19; *p* \< 0.001). Patients significantly preferred no titration over titration in the total sample (OR 1.12; *p* \< 0.001) and in the UK (OR 1.23; *p* \< 0.001), Japan (OR 1.17; *p* \< 0.001), Germany (OR 1.15, *p* \< 0.001), and Brazil (OR 1.09; *p* = 0.01), but not in China (OR 0.99; *p* = 0.75). Patients preferred the preparation associated with a multi-use pen over a vial/syringe in the total sample (OR 1.09; *p* = 0.002) and in the UK sample (OR 1.36; *p* \< 0.001). Needle size and device size were the least important device- and regimen-related attributes in driving preference for the total and country-specific samples.

When patients were asked about hypothetical injectable T2DM treatments, 64.2% of respondents stated that a once-weekly dose would be easiest to follow, while 31.1% selected once daily, and 4.7% thought twice daily would be easiest to follow. When injection-naïve patients were asked about the hypothetical frequency of missing a dose of an injectable diabetes treatment, 60.7% stated that they would never miss a once-weekly dose compared with 54.3% who stated they would never miss a daily dose. If the GLP-1RA injection was administered once weekly, 12.5% of respondents thought they might hypothetically miss a dose at least once every month. If the GLP-1RA injection was once daily, 22.3% of patients thought they might hypothetically miss a dose at least once every month.

Comparison of Hypothetical GLP-1RA Profiles {#Sec10}
-------------------------------------------

In order to determine the influence of attributes other than efficacy, hypothetical GLP-1 RA profiles with equal efficacy were constructed in sensitivity analyses. Total sample data showed that when efficacy was assumed to be equal (1.2-point improvement in HbA1c), injection-naïve patients favored a GLP-1RA profile approximating exenatide QW administered via a single-use pen versus a profile approximating liraglutide QD (OR 3.36; *p* \< 0.001), with 77.0% of the sample preferring the profile approximating exenatide QW. When examined by country, preference for exenatide QW was highest among the UK sample (OR 4.88; *p* \< 0.001) and lowest among the Chinese sample (OR 1.60; *p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Odds ratios for preferring profile approximating exenatide QW (single-use pen) versus profile approximating liraglutide QD (with equal efficacy of 1.2-point improvement in HbA1c), overall and by country. *HbA1c* glycated hemoglobin, *QD*once daily, *QW* once weekly

When efficacy was assumed to be better for liraglutide QD than for exenatide QW administered via a single-use pen (1.2-point improvement in HbA1c vs. 0.8-point improvement in HbA1C), total sample results showed that 70.4% of respondents preferred the profile approximating exenatide QW (OR 2.38, *p* \< 0.001). When examined by country, preference for exenatide QW single-use pen was highest among Japanese respondents (OR 4.22, *p* \< 0.001). The Chinese sample showed no significant preference for one profile over the other (OR 0.90; *p* = 0.38).

When changing exenatide QW's device type to an auto-injector rather than a single-use pen (assuming the same efficacy of a 1.2-point improvement in HbA1c), the strength of preference for the profile approximating exenatide QW increased in the total sample (OR 4.27; *p* \< 0.001), with 81.0% of the sample preferring the profile approximating exenatide QW (auto-injector). When examining country-specific analyses, the OR indicating preference for the profile approximating exenatide QW (auto-injector) compared with the profile approximating liraglutide QD was again highest among the UK sample (OR 8.48; *p* \< 0.001) and lowest among the Chinese sample (OR 1.66; *p* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}). When efficacy was assumed to be better for liraglutide QD than exenatide QW administered via an auto-injector (1.2-point improvement in HbA1c vs. 0.8-point improvement in HbA1c), total sample results continued to show that there was a higher preference for the profile approximating exenatide QW in the total sample (OR 3.03, *p* \< 0.001). Similar trends were observed in the UK (OR 6.14; *p* \< 0.001), Japan (OR 5.75; *p* \< 0.001), Germany (OR 3.57; *p* \< 0.001), and Brazil (OR 3.07; *p* \< 0.001), but not in China (OR 0.94; *p* = 0.59).Fig. 3Odds ratios for preferring profile approximating exenatide QW (auto-injector) versus profile approximating liraglutide QD profile (with equal efficacy of 1.2-improvement in HbA1c), overall and by country. *HbA1c* glycated hemoglobin, *QD*once daily, *QW* once weekly

Discussion {#Sec11}
==========

This multi-country DCE study found that side effects, efficacy, and dosing frequency were most important in influencing preferences among injection-naïve patients. Patients indicated a perception that a once-weekly dosing regimen would result in fewer missed doses than a once-daily dosing regimen. When full medication profiles exhibiting the attributes of two GLP-1RAs with differing key features were compared and efficacy was assumed to be the same, patients preferred the profile approximating exenatide QW (administered via a single-use pen or an auto-injector) over the profile approximating liraglutide QD.

Injection-naïve patients represent an important group of T2DM patients as their preferences have not been influenced by previous experiences of injecting diabetic medication \[[@CR26]\]. Other DCE studies have also examined injection-naïve patients' preferences for the attributes of GLP-1RAs \[[@CR26]--[@CR28]\]. One of these studies also included injection-experienced patients, and focused specifically on the dosing and device-related attributes of hypothetical profiles approximating exenatide QW administered by vial/syringe or a single-use pen compared with a profile approximating liraglutide QD administered via a multi-use pen \[[@CR26]\]. These other studies provide an important context for assessing the influence of injected GLP-1RA attributes on the preferences of patients. In these previous studies, as in the current study, patients' preferences relating to GLP1-RA medication were influenced not only by tolerability but also other dosing and device-related attributes \[[@CR26]--[@CR28]\]. Across all studies, dosing frequency was an important driver of injection-naïve patients' choice of GLP-1RA medication, with once-weekly injections prioritized over once-daily injections \[[@CR26]--[@CR28]\].

Efficacy was found to be less influential in other GLP-1RA DCE studies \[[@CR27], [@CR28]\] versus the current study. However, efficacy was defined differently in these other studies (i.e., achieving HbA1c \<7%) \[[@CR27], [@CR28]\], and the difference between the levels was very small (e.g., 67.9% vs. 68.3% \[[@CR27]\] and 69.1% vs. 71.4% \[[@CR28]\] of patients achieving HbA1c goal of \<7%), thereby reducing its importance as an influential attribute. Even in this study, efficacy played a less prominent role overall when examining preferences for two different full profiles. When efficacy was assumed to be equal, patients indicated a strong preference for a GLP-1RA profile approximating exenatide QW (delivered either via a single-use pen or auto-injector) over a profile approximating liraglutide QD. Even when the profile approximating liraglutide QD was assumed to have better efficacy (1.2 vs. 0.8-point improvement in HbA1c, respectively), patients still favored the once-weekly injection profile. This preference was observed in the total sample as well as within samples from four individual countries, but not in the Chinese sample, where efficacy played a more influential role in driving preferences. The greater influence of efficacy among the Chinese sample could be related to the fact that they had the poorest glucose control compared to the other countries, reporting the highest mean HbA1c level of 9.1%. This finding of suboptimal glucose control among the Chinese sample is consistent with other studies \[[@CR29]--[@CR31]\] that have found inadequate blood glucose control among T2DM patients in China.

The various attributes of medication (including efficacy, adverse events, frequency of dosing, type of delivery device) have an important effect on T2DM patients' adherence to medication \[[@CR10], [@CR32], [@CR33]\]. Currently, nonadherence to therapy is a common problem for patients with T2DM, and it has been associated with increases in morbidity, mortality, and healthcare costs \[[@CR10], [@CR11], [@CR13]\]. If an appreciation and understanding of patients' preference for treatment can be gained and a patient-centered approach is used during clinical decision-making, then adherence is likely to improve \[[@CR7]\]. If adherence can be increased, then improvements in diabetes-related outcomes will be likely, including improvements in glycemic control, and reductions in short-term and long-term diabetes-related complications, and healthcare resource utilization \[[@CR10], [@CR12], [@CR14], [@CR34]--[@CR37]\]. Medication regimens with less frequent dosing regimen are associated with greater adherence to medication \[[@CR38]\]. GLP-1RAs are no exception, with once-weekly injections of a GLP-1RA being associated with greater patient adherence than once-daily injections of a GLP-1RA \[[@CR39]--[@CR41]\].

Understanding patient preference for treatment attributes is needed not only during the clinical decision-making process \[[@CR7]\] to improve adherence and clinical outcomes but also during the development of any diabetes medication. The US Food and Drug Administration encourages the inclusion of patient preference information during premarket approval applications and device labelling \[[@CR42]\]. The development of GLP-1RAs has followed such a patient-centered approach. Aside from the important considerations of efficacy and side effects, consideration during the development process has been given to an attribute which this study indicated was very important to patients, namely dosing frequency. The injectable GLP-1RAs were first available on the market as twice-daily injections (e.g., exenatide), but in line with patient preferences, GLP-1RAs became available as once-daily injections (e.g., liraglutide, lixisenatide), and then as once-weekly formulations (e.g., exenatide, albiglutide, and dulaglutide). Other attributes of injectable medications (such as preparation or titration), identified in this study as being important, have been the focus of the patient-centered GLP-1RA development program \[[@CR17], [@CR43], [@CR44]\].

This study had a number of limitations. DCEs, while a common methodology in eliciting preferences, may not accurately reflect real-world decisions. Since most of the patients were recruited from market research panels, the participants from the five target countries may not be truly representative of T2DM patients in each country. This is particularly the case for the Chinese sample, where 84% of the sample had obtained a university degree or higher, which may have biased the results. Another limitation of this study is that this particular sample included attributes from specific GLP-1RA treatments, exenatide QW and liraglutide QD, thus limiting the generalizability of the findings to other GLP-1RA treatments. Liraglutide QD and exenatide QW were selected for the comparison because they reflect key differences in GLP1-RA treatments, with differences in regimen and side effects, and were available at the time of the study. Furthermore, liraglutide QD is the leading daily treatment for T2DM, and exenatide QW is the first once-weekly T2DM treatment. Nevertheless, other published studies have taken a similar approach comparing two specific treatments and have shown that results from general designs are often different than results for more specific designs involving comparisons of specific treatments \[[@CR27], [@CR28]\]. Additionally, subjects were asked to consider the overall tolerability profile of the treatments based on the most commonly occurring side effects, though the influence of specific side effects on preferences may have varied. Lastly, the number of attributes included in the survey was limited to attributes important to patients related to efficacy, safety, tolerability, and convenience in order to reduce cognitive burden on participants. However, there may be other aspects of treatment that could influence preference for treatment, such as out of pocket cost or time required for training on the use of the device. Thus, the results may not reflect actual market share for these treatments, as other factors may also influence treatment decisions.

Conclusion {#Sec12}
==========

Understanding patient preferences is important for informing new generations of T2DM treatments and ensuring patient-centered care. Since current GLP-1RA treatments vary greatly in efficacy, dosing regimen, and risk of side effects, it is important for healthcare providers to incorporate patient preferences in making treatment decisions as it may increase medication adherence and thus also improve short- and long-term clinical outcomes. The findings from this global study suggest that healthcare providers may need to take into account side effects, efficacy, and dosing frequency when prescribing medications, and drug research and development should focus on these attributes for developing new generations of treatment.
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